|
GDMI Gets FDA Warning for Training Violations
The FDA has warned GDMI, which makes OTC antifungal treatments, about significant GMP violations at a facility in Texas, including flaws in sanitation and training.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives